Next Phase Newsletter

An investment firm based in Spain raised a EUR 200 million fund to make stage agnostic life science deals, investing from early stages to pre-IPO. The firm prefers to lead rounds, particularly in late-stage opportunities. The firm is currently focused on opportunities in Europe. The firm may syndicate international opportunities with US investors. The firm typically reserves EUR 12-15 million per portfolio company.

The firm invests opportunistically in next wave healthcare technologies, including therapeutics, digital health, and medical devices. The firm will also consider diagnostic opportunities on occasion. The firm will invest at any stage of development.

The firm invests globally, but focuses on Europe and prefers to invest in companies with a Spain angle, such as IP or founders from Spain.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture fund based in Canada and backed by a major financial institution in Europe is investing from a new $125 million evergreen fund closed in 2017. The firm looks for companies located in Canada and the United States, with preference given to companies located close to Montreal. The firm makes equity investments in progressive stages, ranging up to $7m and typically leads the round – although the firm is open to co-investing. The firm focuses on companies from early revenue stage all the way up to expansion stage. The firm can help provide portfolio companies with access to the European market.

The firm is interested in all areas of technology, and devotes about 40% of its fund to healthcare. The firm’s investments interests are mostly in medical devices, diagnostics, instrumentation and services, but the firm will also consider investments in breakthrough therapeutic technologies, so long as these will not require lengthy clinical trials. The firm is also interested in novel healthcare IT opportunities such as applications of AI and machine learning in healthcare. The firm seeks highly differentiated, disruptive technology; and does not invest in “me-too” products. The firm primarily invests in companies with revenue-generating products.

The firm seeks disruptive technology companies led by high-quality management teams, and prefers to work with managers who have had previous successes in technology start-ups. The firm has a significant network in Europe and can help portfolio companies commercialize their products and services in European markets.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with a global presence invests in several verticals with the core interest being in scalable, breakthrough technologies. Initial investments may range from $100k – $1M, with up to $10M being invested over the life of the investment, in the form of convertible notes or straight equity. The firm will lead investments or co-invest as a syndicate. The firm will invest in companies on a global basis but is focused on companies in the U.S. and Canada. The partners and advisors of the fund look to add value to portfolio companies through an extensive international network and strong technical expertise.

The firm is generally agnostic to industry and is most interested in unique/novel technologies, with a special interest in AI and blockchain solutions in the healthcare space. While the group is primarily interested in software-based technologies, whether in drug discovery, enterprise software, digital health, etc., medical devices that do not require a traditional regulatory pathway (510(k) or PMA) and that have a core software component will also be considered.

The firm has no strict company or management team requirements and looks to mentor companies/management teams. The firm does not require a board seat along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A wholly-owned venture arm subsidiary of one of the largest health insurers makes strategic investments in healthcare-related innovations that will improve the quality of care and enhance the overall healthcare experience for consumers and providers. 3 important considerations are strategic value, financial return, and improvement in health outcomes. The firm typically participates in Series B or post-Series A bridge rounds. The firm entertains domestic and international opportunities.

The firm invests broadly across healthcare. Recent investments include a lung cancer diagnostics company, a specialty pharmacy company that simplifies medication management, and a behavioral health care management company. The firm expects companies to be past the proof-of-concept stage with demonstration of some traction.

The firm has no specific requirements and can work with all kinds of management teams. The firm is open to both leading and co-investing in financing rounds. The firm may take a board seat when applicable.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment arm of a large, Czech Republic-based financial group that manages 10 sub-funds that total to $400M AUM, has a $22M fund through which the firm actively invests in early-stage life-science companies. The firm prefers to act as the first institutional investor – i.e. it deploys around $250 to $350,000 as initial investment and then provides follow-on investments for companies that achieve a number of milestones. The firm will consider opportunities globally, but mainly focuses its activities in North America and Europe.

The fund is sector agnostic and will consider all innovative technologies within the areas of therapeutics, medical devices, diagnostics, and healthcare IT. About 1/3 of the fund is dedicated to digital health technologies with special interest in the area of mental health. While the fund is mostly indication agnostic, it tends to avoid the over-crowded indications such as oncology/immune-oncology.

The firm is an active investor and takes a dedicated role in its portfolio of companies, providing them with resources and expertise to support company growth. The firm seeks to work with experienced management teams that are working on technology with strong market potential. The firm prefers to act as the lead investor but is open to co-investing as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A seed-stage venture capital fund that seeks to invest in Ontario-based companies operating in the cleantech, information and communication technology, life science and healthcare sectors. The firm is based out of Toronto, Canada and has been investing for over 10 years. The fund is sector-agnostic and invests in several verticals including but not limited to IT, healthcare, and cleantech. The fund makes investments up to $500K in Ontario-based startups, and typically targets 15 deals per year. The fund will invest with VCs and other institutional investors.

The fund is a generalist fund, but within the healthcare space, the focus is on healthcare IT and digital health companies whose core technology is software, whether it be enterprise solutions or more consumer-facing or point of care technologies. Traditional medical devices, biopharma/therapeutics and other life science platform technologies will be also be considered.

The firm requires the company be legally company incorporated and likes to see a formal management structure in place by the time of closing an investment. It’s not necessary that the company have revenues, but the company must have a clear understanding of their path to market and an execution strategy in place that will allow them to move faster than competitors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Canada-based firm founded in 2010 consists of a team of entrepreneurs seeking to invest in small-to-mid sized healthcare & pharmaceutical companies. The firm is open to investing in private companies at all stages from seed through growth and expansion. The firm can act as a co-investor or lead, and additionally can leverage distribution networks and partnerships across 4 continents. Typical allocations are < €25 M structured as equity, and may come from a combination of the partners' personal funds, a family office whose wealth is managed by the firm, or the firm's own fund. Portfolio companies focus on specialty pharmaceuticals, biotechnology, medical devices, & ancillary health services. The firm will invest in English-speaking markets.

The firm’s specialty area is in generic pharmaceutical manufacturing and distribution, and manufacturing and distribution of specialty medical devices. Urology and urogynecology devices, injectable medications, cardiovascular medications, dental devices, vaccines, oncology therapeutics, diagnostics, and surgical simulators are reflected in portfolio companies. The firm is open to reviewing technology in all stages of development. Devices that fit well in the focus and distribution regions of portfolio companies are of particular interest.

The firm looks for strong & accomplished management teams and above all, values innovation, transparency, integrity, execution, and fun. The firm may or may not seek a board seat depending on the structure of the allocation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.